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PENILAIAN AMALAN PENUKARGANTIAN UBAT-UBATAN GENERIK DALAM
KALANGAN AHLI-AHLI FARMASI KOMUNITI DI MALAYSIA DAN AUSTRALIA
ABSTRAK
Banyak negara termasuk Australia telah menggubalkan dasar penukargantian ubat-ubatan
generik untuk mengurangkan beban perbelanjaan ubat. Malaysia juga mengalami cabaran yang
sama dalam menangani peningkatan dalam kos ubat. Namun demikian, tidak seperti Australia,
Malaysia masih belum melaksanakan strategi penukargantian ubat-ubatan generik untuk
menangani masalah ini. Jadi, kajian dalam tesis ini bertujuan menghasilkan data dan garis-
panduan yang dapat membantu pembangunan dasar ubat-ubatan generik di Malaysia. Objektif
kajian ini termasuk menilai dan membanding tanggapan, pengetahuan dan amalan
penukargantian ubat-ubatan generik dalam kalangan ahli-ahli farmasi komuniti di Malaysia dan
Australia. Selain itu, penerimaan pengguna terhadap penukargantian ubat-ubatan generik dan
jumlah penjimatan wang yang terhasil daripada amalan ini juga dibandingkan di antara dua
negara.
Kajian ini merupakan kajian keratan rentas diskriptif nasional. Bahagian I mengkaji tanggapan
dan pengetahuan ahli-ahli farmasi terhadap ubat-ubatan generik melalui borang soal selidik.
Bahagian II mengkaji amalan penukargantian ubat-ubatan generik oleh ahli-ahli farmasi
berdasarkan permintaan terhadap ubat berjenama daripada pesakit. Seluruh populasi farmasi
komuniti di Malaysia (n = 1419) telah dijemput untuk menyertai kajian Bahagian I dan II
menerusi surat. Manakala, kajian Bahagian I di Australia dijalankan menerusi laman web di
mana sesiapa ahli farmasi komuniti yang terdedah kepada laman ini boleh menyertainya. Untuk
kajian Bahagian II, sejumlah 500 buah farmasi komuniti yang mewakili seluruh populasi
farmasi komuniti di Australia telah dipilih secara rawak dan dijemput menerusi surat.
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Sejumlah 219 dan 157 ahli farmasi dari Malaysia dan Australia menyertai kajian dalam
Bahagian I. Peratusan ahli farmasi Australia yang sudi mengamalkan penukargantian ubat-
ubatan generik (93.7%) adalah nyata lebih tinggi daripada Malaysia (66.7%). Ahli-ahli farmasi
Australia dengan nyatanya mempunyai tanggapan yang lebih positif dan lebih berpengetahuan
daripada ahli-ahli farmasi Malaysia dalam isu efikasi, keselamatan, kualiti dan piawaian
pengawalan ubat-ubat generik. Kadar penyertaan dalam kajian Bahagian II adalah 11.1% (n =
157) dan 16.4% (n = 82) masing-masing bagi ahli-ahli farmasi Malaysia dan Australia. Ahli-ahli
farmasi Australia dengan jelasnya mempunyai kadar amalan penukargantian ubat-ubatan
generik (96.4%) yang lebih kerap daripada kumpulan ahli farmasi Malaysia (84.7%). Namum,
rakyat Malaysia memaparkan kadar penerimaan terhadap penukargantian ubat-ubatan generik
(88.9%) yang nyata lebih tinggi daripada rakyat Australia (78.5%). Menerusi penenerimaan
penukargantian ubat-ubtan generik, perbelanjaan dalam pembelian ubat bagi pengguna
Malaysia telah berkurang sebanyak 57.4% berbanding dengan lebih kurang 21.0% bagi
pengguna Australia.
Sebagai kesimpulan, ahli-ahli farmasi komuniti Malaysia perlu memperbaiki tanggapan dan
pengetahuan mereka terhadap ubat-ubatan generik, supaya dapat menyumbang kepada
pembangunan dan pelaksanaan dasar ubat-ubatan generik di masa depan.
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EVALUATION OF GENERIC MEDICINES SUBSTITUTION PRACTICES
AMONG COMMUNITY PHARMACISTS IN MALAYSIA AND AUSTRALIA
ABSTRACT
Many countries including Australia have developed a generic substitution policy designed to
reduce medicines expenditure. In Malaysia, the government is facing a similar challenge of
managing increasing medicines expenditure. However, unlike Australia, the Malaysian
government has not yet implemented the generic substitution strategy. This thesis will provide
some baseline data and guideline for the development of a generic substitution policy in
Malaysia through direct comparison of issues around generic substitution among community
pharmacists in both countries. The study aims to evaluate and compare the perceptions,
knowledge and practices of generic substitution among the Malaysian and Australian
community pharmacists. The patients’ acceptance toward substitution and the resulting cost-
saving were also evaluated and compared between the two countries.
This was a nationwide cross-sectional descriptive study. Part I of the study involved a
questionnaire to assess the pharmacists’ perceptions and knowledge of generic substitution. In
the Part II study, data were progressively collected across the multi-sources brand name
medicines requests encountered by the pharmacists. The entire populations of 1419 Malaysian
community pharmacies were invited in both Part I and II studies via mail. In Australian scene,
the recruitment of participants in Part I study was via self-selection using an anonymous web
based survey. A national representative sample of 500 Australian community pharmacies were
randomly selected and invited via mail in the Part II study.
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Responses were received from 219 and 157 Malaysian and Australian pharmacist respectively
in the Part I study. A higher proportion of Australian pharmacists (93.7%) than the Malaysian
group (66.7%) indicated that they were willing to offer generic substitution. The Australian
pharmacists significantly held more positive attitudes and better understandings of generic
medicines than the Malaysian group, including issues around efficacy, safety, quality and
regulatory standard of generic medicines. The response rate in Part II study was 11.1% (n =
157) and 16.4% (n = 82) respectively for both the Malaysian and Australian arm study. The
Australian pharmacists significantly demonstrated higher generic substitution recommendation
rate (96.4%) than the Malaysian group (84.7%). Nevertheless, Malaysian consumers’
acceptance toward generic substitution (88.9%) was significantly greater than the Australian
citizens (78.5%). Through acceptance of substitution, the Malaysian consumers’ medicines
expenditures reduced by 57.4%, as compared to around 21.0% among the Australian
consumers.
In conclusion, the Malaysian pharmacists’ perceptions, knowledge and practices of generic
substitution need to be improved, if they are to play a future role in supporting the
implementation of a generic medicines policy.
1CHAPTER 1
GENERAL INTRODUCTION
1.1 Introduction
In an ideal healthcare system, every consumer should have timely and equal access to high
quality health services at an affordable cost (Duckett, 2004a). Medicines are an accepted part of
healthcare and there are high level of use of medicines in the community of Australia and
Malaysia. In order to achieve equity and affordability in access to healthcare services including
medicines, a developed country like Australia has implement a national health insurance scheme
(Medicare) and a national medicines scheme (Pharmaceutical Benefits Scheme) to subsidize the
medical expenses of the consumers in both public and private sector. Nevertheless, with the
implementation of a government funded medicines subsidy scheme, the rising cost of
expenditure on medicines has become a worldwide problem. The Australian Pharmaceutical
Benefits Scheme (PBS) expenditure has escalated by an average of 8.4% annually from
AD$2,711 million in 1996-97 to AD$6,227 million in 2006-07 (AIHW, 2008b) due to the
increase in subsidizing expensive new medicines (ADHA, 2007a), pharmaceutical promotions
(Dora & Henry, 2006) and population ageing (Duckett, 2004b; Harvey, 2002). The substantial
increment in government’s medicines expenses has threatened the sustainability of PBS and
subsequently affects the equity and affordability in access to medicines.
The Australian government has reacted to this increasing cost of medicines by encouraging the
uptake of generic medicines. Australia and other countries like US, Belgium and French have
developed policies to encourage generic substitution (GS) (Allenet & Barry, 2003; McManus,
Birkett, Dudley, & Stevens, 2001; Mott & Cline, 2002; Simoens, Bruyn, Bogaert, & Laekeman,
2005). In each of these countries, the community pharmacist is able to undertaken GS unless the
physician does not indicate approval, therapeutic equivalence has not been demonstrated or the
patient declines the substitution. The legislation of this GS policy has contributed to the slowing
2growth rate of medicines expenditures in these countries (Allenet & Barry, 2003; Mott & Cline,
2002; Simoens, Bruyn, Bogaert, & Laekeman, 2005).
Malaysia is a developing country with the government highly subsidized the healthcare services
in public sector. In 2006, 86% of funding in public health sector was provided by the
government (WHO, 2008). The consumer can received their public health services at very low
cost. For instance, charges for an outpatient visit in public hospital is RM1 per visit and this
charge will include the consultation with doctor, any pathological tests and the medicines
prescribed. However, the government subsidized cost for medicines in public hospital increased
from RM 200 million in 1995 to RM 800 million in 2005 with an annual increment of 10-15%
(Anonymous, 2004; Chua, 2005). The burden in medicines expenses has affected the
government’s ability to sustainably finance pharmaceutical in the public sector (Anonymous,
2004). In recent years, patients who visit a public hospital increasingly asked to buy their own
medicines form private pharmacies and clinics due to the non-availability of medicines (Netto,
1999). A survey in 2003 showed 37% of the consumers obtain medicines from private hospital
or clinic and 42% from community pharmacies. In fact, 56% of the consumers view medicines
in private sector as expensive (Babar & Ibrahim, 2003). As there is no National Heath Insurance
Scheme in Malaysia, 74% of source of funding in private sector is from consumers’ out-of-
pocket money (WHO, 2008). As the result, the medicine’s price has become the major
determination of access to affordable medicines in the private health sector.
The Australian government sets medicines pricing control policies towards the medicines listed
on the PBS (PBPA, 2007b). The government as the sole purchaser of medicines from drug
companies has great power in negotiating the price of medicines. If the government does not
accept a price, then the drug is not listed on the PBS. Prescriptions subsidized by the PBS
accounts for around 90% of total prescriptions dispensed in the community and the private
medicine market is rarely commercial viable (AIHW, 2008a). Consequently, the prices of PBS
medicines are controlled at the affordable level for both government and consumers.
3Meanwhile, the Malaysian government does not implement a policy to control the price of
medicines. The manufacturers, distributors and retailers set prices without government control,
thus allowing prices to be determined by market force (PSD, 2007). In the public sector, the
government as the sole purchaser of medicines has significant negotiation power to lower the
medicines prices. Meanwhile, without a National Health Insurance Scheme, the medicines
prices in private sector are out of control of government’s negotiation power. Subsequently, the
wholesale prices of the medicines sold by the drug companies to the public sector are 60%
cheaper than the private sector (PSD, 2007). The branded and generic medicines prices in
private sector were 15-16 times and 6.6-7.0 times higher than the International Reference Prices
(IRPs) which is the median of recent procurement or tender prices for multi-source product
offered by non-profit suppliers to developing countries (Babar, Ibrahim, Singh, Bukahri, &
Creese, 2007). As a result, uncontrolled high medicines prices in private sector have generate
affordability problems among Malaysian consumers (Babar et al., 2007; Saleh & Ibrahim,
2005). In fact, the affordability problem directly reduced the equity in access among the
consumers as the lower income groups have less ability to purchase medicines.
The encouragement to increase the utilization of generic medicines is one strategy to reduce
Malaysian government and consumers’ medicines expenses. In year 2007, the use of generic
medicines in Malaysia is encouraged by the Malaysian government with the publication of the
National Medicines Policy (MOH, 2007a). However, there are no generic medicines or
substitution policies being implemented to driven the generic prescribing and substitution
practices in both public and private sectors. Consequently, the availability of generic medicines
in both public and private sectors was low (Babar et al., 2007) and the problem of increasing
countries’ medicines expenditures remain unsolved.
In conclusion, implementing a Generic Medicines Policy, a National Heath Financing Scheme
and a Medicines Pricing Control Policy are the key elements to improve the equity and
4affordability of Malaysian healthcare services. Malaysian government can consider adopted
these policies from countries which have good performance in their healthcare system.
1.2 Generic medicines use in Australia and Malaysia: A brief overview
The Australian situation demonstrates the role of government and the development of national
policies in introducing change in the health system. In the early 1990s, the Australian
government started to legislate policies to encourage the use of generic medicines under the
PBS (McManus, Birkett, Dudley, & Stevens, 2001). The competition between brand-name
medicines and generic medicines under the PBS began with the introduction of Minimum
Pricing Policy (or Brand Premium Policy) in December 1990 (McManus et al., 2001). This
policy allowed different brands of the same medicine to be listed in the PBS at different prices.
The government only subsidized up to the price of the “benchmark” brand which is the brand
with the lowest price. Later, the pharmacists were permitted GS right with the introduction of
legislation allowing brand (generic) substitution in December 1994 (Lofgren, 2004; McManus
et al., 2001). The introduction of Therapeutic Group Premium (TGP) policy in February 1998
(Lofgren, 2004) also enhanced the utilization of generic medicines. The TGP policy is an
extension of Brand Premium Policy which applies to medicines in a defined therapeutic sub-
group which are similar efficacy and safety. The recent PBS reform which released on 16
November 2006 (ADHA, 2007b; Buckmaster & Spooner, 2007) requires the generic company
to disclose the price of medicines sold to the pharmacy. The generic medicines’ price will be
reduced periodically based on the disclosed price. This reform is aimed to further improve the
generic medicines utilization. The details of these policies will be reviewed thoroughly in
chapter 2.
In Malaysia, currently there is no generic medicines policy covering generic prescribing and
substitution. In year 2007, the Malaysian National Medicines Policy documented that legislation
of generic medicines policy is in the government’s future planning (MOH, 2007a). However,
there is no documented time frame, framework and strategies for the legislation of generic
5medicines policy. The uptake of generic medicines in Malaysia without a driving force of a
generic medicine policy will be discussed in the next chapter.
1.3 Justification for this study
In Australia, although GS has been allowed for Pharmaceutical Benefit Scheme medicines since
1994, the utilization of generics remain low partly due to historical legacy of small price
differentials between branded and generic medicines (Lofgren, 2004). In 2001, the Australian
market share of generic medicines only accounted for around 20% as compared to around 45%
in US and 50% in UK (Lofgren, 2004). Over this period of time, the cost and sustainability of
PBS have been a major concern for the Australian government due to high rate of increment in
PBS expenditure (Buckmaster & Spooner, 2007). A recent PBS reform (2006-2008)
significantly reduces the generic medicines’ price and incentive will be given to pharmacist to
further promote the routine use of generic medicines (ADHA, 2007b). Given the government’s
GS policy to encourage the use of generic medicines to reduce the PBS expenditure (McManus
et al., 2001), it is important to ascertain the factors contribute to the initial low level of generic
utilization in Australia and the effect of recent announced reforms. With the National Health
Insurance Scheme and separation function of prescribing and dispensing between doctors and
community pharmacies, the Australian pharmacists play a major role in helping government to
implement pharmaceutical policies. The success of PBS reform in reducing government and
consumers’ medicines cost rely heavily on the community pharmacists’ GS practices and their
willingness to offer generic medicines to the consumer.
In Malaysia scene, there is a strong need to implement generic medicines policy in both the
public and private sector to reduce government and consumers’ medicines cost and
subsequently improve the equity and affordability aspect. To date, there is limited
documentation on GS practices in Malaysia which provide data to guide the development of
generic medicines policies. The Malaysian community pharmacists are lacking opportunities to
provide GS due to a lack of dispensing separation policy in Malaysia. However, there are annual
6increment in the number of community pharmacies and number of patients who consult the
community pharmacists regarding their choice of medicines treatment (Babar & Ibrahim, 2003).
In fact, recently the Malaysian government has attempted to implement separation of
prescribing and dispensing under the National Medicines Policy of Malaysia (Anonymous,
2008b; MOH, 2007a). Within this context, the pharmacists will have greater role in generic
medicines use process. Therefore, studies are needed to evaluate the community pharmacists’
contribution towards equity and affordability in health through their GS practices. Furthermore,
as both the physicians and consumers are important stake holders in the medication distribution
chain, studies are needed to evaluate their acceptance toward generic medicines.
Through the direct comparison between GS practices among Malaysian and Australian
community pharmacists, this study will provide baseline data to guide the implementation of GS
policy in Malaysia. This study will also indirectly provide guidance for implementing a
National Health Insurance Scheme, a Medicines Pricing Control system and a Dispensing
Separation policy in Malaysia through an evaluation on the Australian community pharmacists’
practices.
1.4 Objectives of this study
The objectives of this comparative study were:
1) To evaluate and compare the GS practices among community pharmacists in Malaysia and
Australia.
2) To evaluate and compare the perceptions and knowledge of generic medicines and
substitution among community pharmacists in Malaysia and Australia.
3) To evaluate and compare the patients’ acceptance towards GS in Malaysia and Australia.
4) To evaluate and compare the cost-saving achieved for the patients from GS between
community pharmacies in Malaysia and Australia.
5) To give recommendations for future action and research based on the results of this study.
71.5 Overview of thesis
Chapter 2, the literature review, starts with an overview of elements in an ideal healthcare
system. A brief discussion of the performance of Australian and Malaysian healthcare systems
is carried out to evaluate whether these two countries’ healthcare systems have reach the ideal
standard. The chapter continues with overview of Australian healthcare system starting from
administration and funding of healthcare delivery system to development of pharmaceutical
policies and finishes with a consideration of how the practice of pharmacists is influenced by
various government policies. The examples of relevant Australian government policies, the
Pharmaceutical Benefits Scheme and the generic medicines policy are discussed in depth.
The chapter continues with overview of Malaysian healthcare system. The overview starts with
administration and funding of health services, followed by pharmaceutical situation in Malaysia
and finally the practices of pharmacists driven by the pharmaceutical conditions in Malaysia.
All the missing elements in Malaysian healthcare system in order to achieve the level of ideal
health system are discussed in depth. Issues related to the use of generic medicines in Malaysia
are also discussed.
Further discussion in this chapter includes the outcome of implementing GS policy from a
worldwide perspective. This discussion is followed by a thorough literature review on the
perception and knowledge of physicians, pharmacists and consumers towards the use and
substitution of generic medicines and cost-saving achieved from GS practices in worldwide
including Malaysia and Australia.
Chapter 3 details the methodology used for the studies in this thesis. Chapter 4, 5 and 6 are
consolidated as Part I of the thesis which consists of the methodology, results and discussion of
the first study which is a national survey designed to assess and compare the perception and
knowledge of generic medicines and substitution practices among the Malaysian and Australian
community pharmacists. Chapter 4 presents the findings from survey conducted with Malaysian
8community pharmacists and discussion based on the findings. Meanwhile, chapter 5 details the
findings from survey conducted with Australian community pharmacists and subsequent
discussion based on the findings. Chapters 6 compare and discuss the findings from the
Malaysian and Australian arms of the survey and draw conclusions from the findings.
Chapter 7, 8 and 9 are grouped as Part II of the thesis. Part II details the methodology, results
and discussion of the second study which is a nationwide study involving community pharmacy
across Malaysia and Australia to assess and compare the GS rate, patient acceptance and cost-
saving achieved from substitution. Chapter 7 presents the findings from the Malaysian arm of
the study and the findings are discussed. Chapter 8 describes the findings of the Australian arm
study and related discussion. Finally, in chapters 9 the results from the both Malaysian and
Australian arms study are compared and discussed.
In Chapter 10, conclusions from the discussion from the two studies are presented. A summary
and a set of recommendations to improve the health system in both countries and for future
research are provided.
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LITERATURE REVIEW
2.1 The ideal healthcare system
According to World Health Organization (WHO), health system is described as “all the
activities whose primary purpose is to enhance, restore, or maintain health” (WHO, 2000). The
WHO defined the characteristics of a well performing health system as one that should achieve
three fundamental goals, which are: (i) it should be able to achieve good health, (ii) be
responsiveness to the expectations of the population, and (iii) be affordable and equitable in
distributing the costs of the health system across the population (termed “fair financing”)
(WHO, 2000).
To achieve “good health” means to maximize the health status of the population over people’s
whole life cycle. Meanwhile, “responsiveness” is measure of how the system responds to non-
health aspects, and whether it meets the population’s expectations of how people should be
treated by healthcare providers or non-personal services. It is an assessment of people’s
satisfaction with the purely medical care they receive, such as waiting times for treatments and
respect for the dignity of the person. Finally, “fair financing” means that the risks each
household faces due to the expenses of the health system are distributed based on affordability
to pay rather than to the risk of illness. The system should be based on fair finance to protect
individuals from catastrophic healthcare cost. Nobody will be forced into poverty because of
healthcare expenses (WHO, 2000).
Loewy has also attempted to define an “ideal” healthcare system. He defines it as one
unencumbered by economic considerations and provide an ample supply of well-paid healthcare
professionals who would supply culturally appropriate optimal healthcare to the level defined
by patients (Loewy, 1998). This “ideal” health system only can exist in a society with unlimited
resources for all social goods, but in reality such an ideal society hardly exists. It is more
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rational to achieve a well perform healthcare system within the limits of what is possible and
would optimize but not maximize the desired goals (Loewy, 1998).
2.1.1 Goals of an ideal healthcare system
Apart from WHO’s three overall goals of health system, others have suggested other goals for a
health system. The United Nations’ Committee on Economic Social and Cultural Rights set
availability, accessibility, acceptability and quality of health services as goals of health system
(UN, 2000). Hall and Griner proposed that an “ideal” health system must fulfill the goals of
access, quality, affordability and professional satisfaction (W. J. Hall & Griner, 1993). Duckett
suggested that a healthcare system can be evaluated with a two dimensional approach: quality,
efficiency and acceptability on one dimension and equity on another (Duckett, 2004a).
However, the WHO views the above elements like affordable, equitable, accessible, sustainable,
good quality and efficiency as instrumental goals that will leads to final goals of health system
(WHO, 2000). For instance, a health system which achieved instrumental goal of high
accessibility will increase the number of peoples who utilize it and leads to final goal of
improvement in health (WHO, 2000).
There are links between the “accessibility to healthcare” and others instrumental goals in the
healthcare system (ABS, 2007, 2008b; WHO, 2007). Penchansky & Thomas define “access” as
a general concept that summarizes a set of more specific dimensions which are availability,
accessibility, accommodation, affordability and acceptability which describing the fit between
the patient and the healthcare system (Penchansky & Thomas, 1981). Meanwhile, Gulliford and
colleagues suggested that “access to healthcare” should be measured on at least four dimension
which are affordability, physical accessibility, acceptability of services and equity of access
(Gulliford et al., 2002). The deviations in point of views between experts and overlapping of
context in the elements of health systems goals lead to difficulty in standardizing the assessment
of health system performance.
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2.1.2 Performance indicators for an ideal health system
It is important to evaluate the performance of a health system in order to identify any weakness
and subsequently developed strategies to improve the system. Recently, Kruk & Freedman have
developed a framework for health system performance measures based on a systematic review
of 305 research articles on indicators used in measuring health system performance (Kruk &
Freedman, 2008). The starting points of the framework are the input of policies, funding and
arrangement of health organization which aims to generate an effective, equitable and efficient
health system. The framework groups together all the contributions of the instrumental goals
(termed “output”) of health system into three major outcome measures which are
“effectiveness”, “equity” and “efficiency” (see Figure 2.1).
This framework define an “effective” heath system as one that is able to provide timely access
to all of the components required of a health services, and ensures efficacious and safe care
leading to improvement in health. The component of “effectiveness” in the healthcare system
includes the outputs of “access” and “quality of care” which will lead to outcomes of “health
status” and “patient satisfaction”. The “access” to healthcare further divided into three
components of measurements; “availability” of healthcare services, “utilization” of services and
“timeliness” in access to services. The last component of “effectiveness” is “quality of care”
which stress on “efficacy” of treatment, “safety” of treatment and “continuity” in access to care
(Kruk & Freedman, 2008).
To achieve “equity” in health, all the health disparities which are unfair such as those due to
poor access to services, unhealthy living or working conditions, or downward social mobility
caused by ill health must be addressed. These disparities commonly related to social advantage
or disadvantage such as wealth, gender, race or ethnicity. Therefore, the measurements of
“equity” in healthcare system include “equitable access to care” which will result in “equitable
health status”, “fair financing” and “risk protection” from financial ruin due to catastrophic
health expenditures, which means the health services must be “affordable” for the whole
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population. Equity in access to care is measure by analyzing the markers of effectiveness
(access, quality and patient satisfaction) by income quintile, ethnicity, gender and geographic
location. Meanwhile, “equitable health status” involves measuring mortality rates for lowest
income quintile, women, immigrants, members of ethnic groups and populations in remote area.
Measures of “equitable financing” can be performed by analysis of the distribution of
government health financing to different parts of the country and different social groups,
progressivity of financing methods (tax, out-of-pocket) and extent of out-of-pocket payments,
indirect payments and informal fees for essential services. The component of “risk protection”
can be measured by proportional of population with catastrophic health expenditures and
incidence of impoverishment as a result of health payments (Kruk & Freedman, 2008).
“Efficiency” in health systems means to extract the maximum health gains from inputs of
policies, funding and arrangement of organization. To achieve efficiency, the first requirement
is the “adequacy of health funding”. “Cost and productivity”, and “administrative efficiency”
are another two dimensions of efficiency in health system. “Adequacy of funding” can be
measured by per capita healthcare spending. “Cost and productivity” involves measurements of
cost per case treated (per hospital day, per out patient visit) and cost-effectiveness ratios for
specific services as compared to alternative services. Lastly, “administrative efficiency”
evaluates the ability of health system to maximize the value of health workers and the value of
the patients’ time. The indicators for administrative efficiency include health worker attrition
rates, health worker morale, frequency of supervision and training and availability of skilled
worker when needed (Kruk & Freedman, 2008).
The components of “health status improvement”, “patient satisfaction” and “fair financing and
risk protection” in the Kruk & Freedman framework (Kruk & Freedman, 2008) are equivalent to
the three major goals of “good health”, “responsiveness to people’s expectation” and “fair
financing” in the WHO’s framework (WHO, 2000). However, the WHO’s framework excludes
health system’s instrumental goals of accessibility and efficiency (WHO, 2000). Both
frameworks are useful for policy makers & researchers to evaluate the performance of health
systems and impact of changes in policies, funding or organization structure and subsequently
develop appropriate strategies to improve the health system. The frameworks also allowed the
comparison between different health systems become easier.
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growth rate of 1.5% in 2007 (ABS, 2007). The population is ageing with the percentage of
elderly population (over 65 years) was 13.3% whereas 19.4% of the population was below 14
years in 2006 (WHO, 2007). In 2005-06, the per capita GDP was US$36,759.00 with the
growth rate of 7.8% and the government spend 9.0% of GDP in the healthcare (AIHW, 2007;
WHO, 2007). Meanwhile, Malaysia is a middle-income developing country with a size of
330,000 square kilometer (WHO, 2008). The population in 2008 is 27 million and annually
growth at 1.9% as of 2006 (DSM, 2008b; WHO, 2008). The Malaysian population is relatively
young with 32.4% below 14 years and only 4.3% were elderly in 2006. The per capita GDP was
US$5227.50 with the growth rate of 8.4% in year 2005. At the same year, the total expenditure
on health was 3.5% of GDP (WHO, 2008).
A duel health system with both the public and private health services co-exists in Australia and
Malaysia. Both the Australian and Malaysia governments highly subsidized the medical and
medicines expenditure in public sector with limited contribution from the consumers. The
Australian government implement national health insurance scheme to cover the medical and
pharmaceutical expenditure in private sector. Conversely, there is no universal financing
scheme in Malaysia and the expenditure in private health sector mainly funded through
consumers’ out-of-pocket money.
In year 2000, the WHO has assess the performance of healthcare system in 191 countries based
on their ability to achieve the goals of “good health”, “responsiveness” and “fair financing”
(WHO, 2000). On the other hand, there are various studies on different dimension of health
system performance being carried out in Australia and Malaysia. The aims of the following
sections are to compare the performance of Australian and Malaysian health system and
identified areas which needed to be improved.
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2.1.3(a) Health status
The WHO used “disability-adjusted life expectancy at birth (DALE)” as the indicator to assess
the overall population health status and to evaluate how far the objective of good health is being
achieved (WHO, 2000). DALE is a measurement of life expectancy adjusted to take account of
time lived with a disability. A population with good health status is indicated by higher DALE.
Australia rank number two in the WHO World Health Report 2000 with the total population’s
DALE of 73.2 years (70.8 years for male; 75.5 years for female) as compared to Malaysia
(ranked 89) with the DALE of 61.4 years (61.3 years for male; 61.6 years for female) (WHO,
2000). Another indicator for population’s health status is life expectancy at birth which does not
adjust for the time lived with a disability. The different between these two countries were 79
years for males and 84 years for females in Australia (ABS, 2009) as compared to 72 years for
males and 77 years for females in Malaysia in 2007 (DSM, 2009).
2.1.3(b) Responsiveness
The WHO used two criteria to assess the responsiveness of a healthcare system. The first
criteria is associated to respect for human beings like (i) respect for the dignity of the person;
(ii) confidentiality on personals health information and (iii) autonomy to participate in choices
about one’s own health. The second criteria is client orientation which include (i) prompt
attention, (ii) amenities of sufficient quality, (iii) access to social support network and (iv)
freedom in choice of provider. The overall responsiveness in Australian heath care system was
ranked 12-13 whereas Malaysia was ranked 31 among 191 countries (WHO, 2000). Another
survey in 2001 showed majority (63%) of Australian rated the medical care services in Australia
as excellent or very good (Blendon et al., 2002).
2.1.3(c) Fair financing and affordability
The WHO measured the fairness of the distribution of financial burden with an index which
range from zero (extreme inequality) to 1 (perfect equality). Australia ranked 26-29 with the
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index value of 0.971. However, the fair financing in Malaysia healthcare system is far behind
Australia with the ranking of 122-123 (index value = 0.917) (WHO, 2000).
The health system is perfectly fair financed if the ratio of total health expenditure to total non-
food expenditure is identical for all households, independently of their income, health status or
use of health system. The funding would be unfair either if the poor spent a larger share than the
high income groups or the high income groups spent more, as their higher capacity to pay. By
paying the equal fraction, the high incomes would be subsidizing the poor. Overall, countries
with universal health insurance scheme have the index value close to 1. In contrast, inequality
happen in countries with high out-of-pocket health spending and the index value is far from 1.
The Malaysian’s out-of-pocket expenditure as percentage of total expenditure was 42.4% as
compared to only 16.6% in Australia (WHO, 2000). The high out-of-pocket health expenditure
in Malaysia is mainly due to the absence of social health insurance. Malaysia faces difficulty in
implementing national health financing scheme due to the low general taxation which account
for only 10.4% of GDP (2007 data) (DSM, 2008a; MOF, 2008). The low taxation is unable to
generate a funding pool with high capacity to cover the health expenses of whole population.
This problem generally happens in developing country with general taxation on average account
for less than 20% of GDP (WHO, 2000). The high general taxation in Australia which account
for 30.5% of GDP in 2006-07 (ABS, 2008a) enable the existence of national health insurance
coverage.
There are studies particularly looking at affordability of medicines in private sectors of
Malaysia which can be a barrier to access to adequate treatment. Affordability is not an issue in
public sector because the medicines supply to the patients is almost free (Chua, 2005). The
Malaysian government has no policy to control the prices of medicines and believes that market
competition between drug companies is capable to generate fair and reasonable price (Babar et
al., 2007). However study showed Malaysia has higher medicines prices as compared to other
countries. For instance, in 2004, the median price ratio (MPR) of generic amitriptyline was 6.89,
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which was higher than India (3.89 to 4.99), Indonesia (2.23), Kazakhstan (4.42) and Uganda
(3.44) (WHO, 2006). The MPR is the comparison of the local median unit price of the medicine
with the International Reference Price (IRP). In fact, a recent study showed the branded and
generic medicines prices were 15-16 times and 6.6-7.0 times higher than the International
Reference Prices (Babar et al., 2007). Under this circumstances, the affordability of medicines
become a raised concern because unaffordable to medicines can causing prescription non-
compliance (Kennedy, Coyne, & Sclar, 2004). A survey in 2003 showed majority (79%) of
consumers purchased medicines from private sector (37% from private hospitals/clinics; 42%
from pharmacies) as compared to 13% obtain from government hospitals. Among the
respondents, 56% perceived medicines as expensive and 68% urged that government should
control the prices (Babar & Ibrahim, 2003). Meanwhile, a study to measure affordability of
medicines in community pharmacies showed that average 3.7 weeks of lowest government
wage (US$46.05 per week) was needed for treating moderate pneumonia (Saleh & Ibrahim,
2005). Another study was conducted to measure affordability of branded and generic medicines
in private sectors. A one month treatment of Losec® (omeprazole 20mg daily) cost two weeks of
lowest government wage while treatment using lowest-price generics cost about 3-4days’ wage
(Babar et al., 2007). Both studies concluded that medicine prices were hardly affordable for
lowest income families. However, the generic medicines are more affordable than branded
medicines. A survey in 2007 showed the branded medicines were about twice (114%) more
expensive than generics in private sector (PSD, 2007). Nevertheless, without a generic
medicines policy in Malaysia, the availability of generic medicines in private sector was low.
The median availability for lowest-price generic was only 45% in private clinics and 43% in
community pharmacies (Babar et al., 2007). The low availability may reduce the utilization of
generic medicine which is more affordable for the lower-income groups.
Australia on the other hand supports a national subsidized medicines scheme (The PBS) with
patient sharing a proportional of the costs, and the taxpayer paying for the larger portion. This is
a deliberate policy initiative designed to contain the cost of medicines to the advantage of the
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Australian taxpayer. This is a two stage process; the first is the focus on cost effectiveness when
listing a new pharmaceutical (or brand) onto the PBS, and the second is a cost sharing
mechanism whereby the public pay a co-payment system. As of 1st July 2008, when purchasing
a medication under the PBS, the maximum a general patient and a concessional patient (low-
income citizens and welfare recipients) paid is the patient co-payment of AD$31.30 and
AD$5.00 respectively and the balance is subsidized by the scheme (ADHA, 2008b).
Nonetheless, in the past decade, the rapid increment in PBS expenditure has force the
government to release the burden of PBS expenditure through increased in patients’ cost-
sharing (Harvey, 2002, 2005). The PBS patients’ co-payment were only AD$20.00 for a general
patient and AD$3.20 for a concessional patient in year 1997 and the amount increased to
AD$30.70 and AD$4.90 respectively in 2007 (Sweeny, 2007b). The increment in patient co-
payment will have negative impact in both affordability and accessibility particularly among the
financial disadvantage groups (Harvey, 2002). Data from the 1998 and 2001 Commonwealth
Fund International Health Policy survey found that inequity in access to healthcare and
medicines still existed between lower and higher income-groups in Australia due to a financial
barrier (Blendon et al., 2002; Donelan, Blendon, Schoen, Davis, & Binns, 1999; Schoen et al.,
2000; Schoen & Doty, 2004). Twenty one percent of lower income-groups reported a time when
they did not fill a prescription due to cost as compared to 18% of higher income-groups.
Conversely, United Kingdom with limited use of patient co-payment only have 7% of both
lower and higher income citizens reported a time when they were noncompliance to prescription
due to its cost (Blendon et al., 2002). Apart from rapid increase in PBS co-payment, another
reason for inequity in access to healthcare in Australia could be that the higher income-groups
were more likely than lower income-groups to purchase supplemental insurance coverage for
their medical and medicines expenses. Therefore, the lower-income citizens are more exposed
to financial burden due to lack of private insurance coverage (Schoen & Doty, 2004).
A few strategies have been carried out by the Australian government to ameliorate the financial
barriers of access to medicines. Firstly, there are Safety Net provisions for a reduction in the
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patient contribution once a family has exceeded a certain amount on PBS subsidized medicines
in a calendar year. The general patients pay only AD$5.00 per PBS prescription while the
concession patient receives free PBS medicines for the rest of the calendar year. This strategy
protects patients and families who needed large quantity of PBS medicines (ADHA, 2008b;
Harvey, 2002). The second attempt is to control the PBS medicine prices to limit the PBS cost.
The medicines prices are set by refering to the lowest-priced brand for the same medicine
(Minimum Pricing Policy or Brand Premium Policy) or the medicines within a defined
therapeutic sub-group with similar health outcome (Therapeutic Group Premium Policy)
(Lofgren, 2004; McManus et al., 2001). The government only subsidizes up to the price of the
lowest-priced brands and the consumers are required to pay the balance above the base price. As
the result of these policies, the average price differences between a branded and a generic
medicine was only AD$3.03 in year 2008 (PBPA, 2008). In year 2005, the government
mandated a 12.5% price-cut on the launch of the first generic brand of drug for an already PBS-
listed drug (Abbott, 2005). The recent PBS reform in November 2006 required the generic
companies to disclose the actual market price of the drug as a condition to be listed in the PBS.
Staged price cuts will apply until the price of the medicines is based on the disclosed price
(ADHA, 2007b; Faunce & Lofgren, 2007). The implementation of GS policy in 1994 is another
strategy to improve affordability of medicines and reduced the government’s PBS cost through
increasing the utilization of generic medicines (McManus et al., 2001). The recent PBS reform
further encourages the use of generics by giving pharmacy owner an incentive of AD$1.50 to
dispense a lowest-priced generic medicine (ADHA, 2007b; Faunce & Lofgren, 2007).
2.1.3(d) Overall measure of attainment
In the World Health Report 2000, the achievement in “health status”, “responsiveness” and “fair
financing” have been combined into a single overall measure of attainment by an index value.
Australia ranked 12 (index value = 91.3) in the overall goal attainment whereas Malaysia ranked
55 with the index value of 80.8. Japan is the top country with the index of 93.4; meanwhile
Sierra Leone has the lowest index score of 35.7 (WHO, 2000).
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2.1.3(e) Efficiency
The efficiency of Australian and Malaysian healthcare system were ranked 32 and 49
respectively in the WHO report. The measurement was done by relating the overall measure of
attainment to the resource use and human capital in the healthcare system (WHO, 2000).
2.1.3(f) Conclusions
Generally Australia has better performed in regards to the performance indicators described
above than Malaysia. The performance of Malaysia healthcare system in “health status”,
“responsiveness” and “efficiency” are relatively high among the 191 countries in the WHO
World Health Report (WHO, 2000). However, Malaysia performed unsatisfactory in “fair-
financing”, particularly in affordability of medicines which will directly affect the equity and
overall health outcome. In short, the Malaysian government can consider adapting the
successful policies in the Australian health system to achieve fair financing and affordability in
relation to medicines for its citizens. The high performance of “fair financing” in Australian
health system is due to the existence of national subsidized heath scheme which reduces the out-
of-pocket medical and medicines expenditure. In addition, the Minimum Pricing Policy which
controls the medicine prices at affordable level and cost-containment mechanisms like generic
medicines policy further reduced the consumers’ medicine expenditure.
2.2 Australian healthcare system
2.2.1 Administration and funding of health services in Australia
Australia is a federation consisting of a national government (the Australian or Commonwealth
government) and eight State and Territory governments. In addition, there are local councils in
each State that have responsibility for a limited range of services delivered to the local
community (for example, sanitation, local roads, planning and some public health services such
as immunization) (Pink, 2008).
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The majority of taxes are collected by the Commonwealth government which funds an
increasing proportion of programs and services throughout Australia. The States and Territories
have a range of clearly defined constitutional activities. The Australian health system is
administered and funded by all three levels of government (Commonwealth, state/territory and
local) and between the public and private sectors (AIHW, 2008a; Pink, 2008). The
Commonwealth government is responsible for most of health service funding, operates a
universal health insurance scheme (Medicare) and a subsidized medication scheme (the
Pharmaceutical Benefits Scheme), regulation and licensing therapeutic products, a range of
services and associated workforce and national health policy leadership.
Figure 2.2: Flow of funding in Australia
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taxation and a 1.5% income tax levy (with exceptions for low-income groups). The high-income
earners without private health insurance is imposed an additional levy of 1% (Pink, 2008).
Medicare administers two programs relevant to the studies conducted in this thesis:
i) Medicare Benefits Scheme (MBS) - component of Medicare which provides rebates to
patients for health services provided by privately practicing doctors (GPs), specialists,
optometrists and other allied health practitioners. For instance, for a GP visit, the doctor can
send a bill directly to Medicare and must accept the government payment (rebate) as full
settlement of the account. Conversely, the GP can bill the patient and there is no limit on that
can be changed. The patient can claims the Commonwealth set rebate from Medicare for the
GP’s fee later (Pink, 2008). MBS does not cover people attending a public hospital which falls
in the States’ responsibilities.
ii) The Pharmaceutical Benefits Scheme (PBS) - component of Medicare which provides
rebates to patients for a wide range of necessary and cost-effective prescription medicines
obtain from community pharmacy (Graham, 1995; Sansom, 2004). The Medicare eligible
patients are categorized into general and concessional patients (pensioners, low-income earners
and welfare recipients). When purchasing a PBS medicine, the maximum price a general patient
pay is the patient co-payment contribution which, as of 2008 is AD$31.30. Meanwhile, a
concessional patient only pays AD$5.00 per prescription item. The PBS pays the pharmacist the
balance between the co-payment and the dispensed price of the medicine as listed in the PBS.
The PBS protects the patients and families who required large amount of PBS medicines from
the cumulative effect of patient co-payment through a Safety Net Scheme with an annual
threshold. In 2008, the Safety Net Thresholds are AD$1141.80 (general patient) and AD$290.00
(concession patient). When a patient incurs cumulative costs singly or as a family above the
safety threshold amount during the course of a year, the general patients are entitled to PBS
medicines at the concession price while concession patient can obtain PBS medicines free of
charged for the remainder of the year (ADHA, 2008c).
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In certain circumstances, patients may pay an extra fee in addition to the co-payment. This extra
patient contribution is known as either a “brand premium” or “therapeutic premium” and has
resulted where there is disagreement between the manufacturer and the government over the
dispensed price for that benefit item (ADHA, 2008c). A further explanation of brand and
therapeutic premium will be in Section 2.2.4(a) of this chapter.
In 2005-06, Australia’s estimated total pharmaceutical expenditure was AD$10,551 million
which mostly funded by the government (83.0%) and the remaining 17% was covered by
individual out-of-pocket expenses. The majority of this pharmaceutical expenditure was for
benefit-paid pharmaceuticals (69.1% or AD$7,286 million), which also mostly funded by the
government (80.6%) and 16.1% was due to patient co-payment (AIHW, 2007).
2.2.1(b) Private health insurance
The private health insurance co-exists with and supplements the Medicare system. It covers part
or all of private treatment charges to private patients, in either a public or private hospital. It
also helps to fund some ancillary services such as dentistry and physiotherapy (J. Hall, 1999;
Pink, 2008). In 1999, the Australian government started to subsidized private health insurance
premium through a 30% rebate, with higher rebates for elderly (35% for aged 65-69 years and
40% for aged 70 years and over) (Pink, 2008). Since then, the population with private hospital
insurance coverage increased drastically from 31% in 1999 to 44% in 2007 and the
governments increased their share of public and private hospital funding by 5.6% due to the
effect of this private insurance rebate scheme (AIHW, 2007; Pink, 2008).
2.2.1(c) Public hospital sector
The public hospital is the responsibility of the State or Territory governments but is jointly
funded by the Commonwealth (J. Hall, 1999; Pink, 2008). Patients who admitted to public
hospital can choose to be treated as public or private patients. Public patients receive treatment
from doctors and specialists nominated by the hospital and are free of charged for the treatment.
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Private patients can select their personal healthcare providers, but charges are applied for all of
the services. Medicare subsidizes the fees charged by doctors and private health insurance
covers medical fees and the hospital costs. The public hospitals have their own pharmacies
which provide free access to medicines for admitted Medicare eligible patients. The State and
Territory governments are responsible for the cost of drugs used in public hospitals. However, a
recent initiative is changing this when a state or territory government enters into a reform
agreement with the Australian government, in which medicines provided to non-admitted
patient may be charged to the PBS (Pink, 2008). In 2005-06, there were 755 public hospitals,
including 19 psychiatric hospitals. The public hospital beds representing 68% of all beds in the
hospital sector with the ratio of 2.7 beds per 1,000 populations (Pink, 2008).
2.2.1(d) Private health sector
The private health sector funds around one third of all healthcare, with 19% of total health
expenditure was funded by consumers’ out-of-pocket expenses and the rest was funded by
government and private health insurance (Pink, 2008). The private health services include:
i) Medical and allied health practitioners.
ii) Community pharmacists who dispensed most prescribed pharmaceuticals.
iii) Private age-care facilities which provide high-level residential aged-care beds.
iv) Private health insurers provide rebates for ancillary health services and hospital treatment as
a private patient.
v) Injury compensation insurers providing worker’s compensation.
vi) Third-party motor vehicle insurance.
vii) Private hospital which provide one-third of all hospital beds in Australia. There were 547
private hospitals in operations in 2005-06.
